KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Tax Provisions (2016 - 2025)

Eli Lilly (LLY) has disclosed Tax Provisions for 17 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 159.11% year-over-year to $1.6 billion, compared with a TTM value of $5.1 billion through Dec 2025, up 143.59%, and an annual FY2025 reading of $5.1 billion, up 143.59% over the prior year.
  • Tax Provisions was $1.6 billion for Q4 2025 at Eli Lilly, down from $1.6 billion in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.6 billion in Q3 2025 and bottomed at $113.8 million in Q4 2021.
  • Average Tax Provisions over 5 years is $481.5 million, with a median of $306.0 million recorded in 2023.
  • The sharpest move saw Tax Provisions plummeted 67.7% in 2021, then skyrocketed 325.83% in 2023.
  • Year by year, Tax Provisions stood at $113.8 million in 2021, then soared by 39.46% to $158.7 million in 2022, then surged by 100.95% to $318.9 million in 2023, then skyrocketed by 97.08% to $628.5 million in 2024, then soared by 159.11% to $1.6 billion in 2025.
  • Business Quant data shows Tax Provisions for LLY at $1.6 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.1 billion in Q2 2025.